Table 2.

Combined effects of PF00299804 with molecular-targeted agents

Combination index (ED50)
Cell lineTrastuzumabCP751871PD0325901PF04691502
N870.5541516550.5415024020.6698371530.96706862
SNU100.0005014090.3019883050.321073909
HGC270001.108204395
A3KAW0001.000689376
SNU160000
MCG8030000
KATOIII000.8698522571.069276673
IM950.6194012371.2770162720.3052041530.589515856
AGS000.8717954710.67466387
MKN740300.48189660.3304465350
HS746T0001.561134324
MKN45001.0093026641.085300975
MCG8030000
MKN10002.850976027
IM95M00.1758146870.6218388120.742345251
SGC79010000
GAM0160001.521582768
FU970000.91051368

NOTE: Shown are combination index for the combination of PF00299804 with molecular-targeted agents (trastuzumab, CP751871, PD0325901, or PF04691502) at the 50% fraction affected in 18 gastric cancer cell lines (CI > 1: antagonistic effect; CI = 1: additive effect; CI < 1: synergistic effect).